Biotech failure, 2002 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who started this subject	12/19/2002 10:50:23 AM
From: tuck	of 130

>>BOTHELL, Wash.--(BUSINESS WIRE)--Dec. 19, 2002-- ICOS Corporation ("ICOS")(Nasdaq:ICOS - News) today announced that an Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 study of Pafase® (recombinant human platelet-activating factor acetylhydrolase) in severe sepsis be concluded following an interim analysis that failed to demonstrate clinical benefit. The primary efficacy endpoint was 28-day all cause mortality. The analysis included results from over 1,250 patients in the COMPASS (COntrolled Mortality trial of Platelet-Activating factor acetylhydrolase in Severe Sepsis) clinical study. As a result of the IDMC recommendation, ICOS is halting patient enrollment in the clinical study and will discontinue further work on Pafase.<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next